Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.

Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.

Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.

In this week's EuroBiotech Report, GSK plans R&D cuts, Genfit gets breakthrough status and Kiadis pens deal to buy CytoSen. 

The breakthrough tag comes as Genfit gears up to start a phase 3 trial in the indication later in the year.

The drug ACT017 from Acticor targets GPVI, a platelet protein that's critical for blood clot formation but doesn’t affect the regulation of bleeding.

The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.  

Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company advances four RNA-targeting drugs.

Talaris Therapeutics raised $100 million to move its cell therapy for kidney transplant patients into phase 3.